CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01657331
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-25T00:08:54.116772+00:00
Published At: 2026-06-24T00:00:00+00:00
Record Updated At: 2026-06-24
Results Posted At: 2026-06-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-24"
protocolSection.identificationModule.nctId: "NCT01657331"
protocolSection.identificationModule.officialTitle: "A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-06-24"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.